Aduhelm Boosts State Officials’ Push To Close Formularies, Hike Rebates

By Gabrielle Wanneh / July 13, 2021 at 1:03 PM
A state health policy group says FDA’s controversial approval of the Alzheimer’s Drug Adulhelm casts new light on Medicaid directors’ calls for policies to limit state spending on high-cost accelerated approval drugs, and the group is trying to gin up additional state interest in pushing the ideas. The group points to two main proposals, both of which would need federal approval: Letting state Medicaid programs exclude accelerated approval drugs from their formularies; and letting states increase rebates for accelerated approval...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.